The data presented was from 33 patients who have completed five years of treatment with Jivi®.
The data from both studies confirmed the safety and sustained efficacy of Eloctate ® and Alprolix ® over four years of treatment.
The two recommendations address gene therapy clinical trials, and use of emicizumab-kxwh.
This chapter includes new product approvals and Guelcher explains that ITI could be the solution to eradicate the inhibitor itself.
NHF, Impact Education and the Postgraduate Institute for Medicine offers accredited educational opportunties for healthcare providers on managing and treating females with bleeding disorders.
The Genentech therapy has been approved for routine prophylaxis in adults and children with or without factor VIII inhibitors.
It's not too late to provide your feedback and help drive the critical direction of inhibitor research. Deadline is November 12th!
Investigators study early risk factors and prevention of cardiovascular disease in children and young adults with hemophilia.
By accessing this activity healthcare providers will increase their knowledge of the potential role of gene therapy to address challenges in current hemophilia treatment.
The activity will examine the technology behind the emerging approaches to gene therapy in hemophilia.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car